Our peptide portfolio is the asset obtained by the acquisition of TXP Pharma, and comprise short peptides being analogues of the melanocyte stimulating hormones (MSH), the endogenous compounds in the immune system that bind to and activate the melanocortin receptors (MCR).
The peptide portfolio is based on a platform technology for modification of peptides called branched amino acid probes (BAP), that is very well protected through the patent portfolio SynAct has acquired.
One of the effects of the BAP-modification is that that the MSH analogues seem to be more effective than the natural compounds in our preclinical research.
TXP-11
The most progressed peptide in the portfolio is TXP-11, which has been characterized in preclinical studies and tested in toxicology studies allowing us to proceed into clinical research, although some preclinical research is still outstanding before a clinical trial application can be filed. The plan is to be ready for phase 1 in 2025.
Manufacture and formulation of the peptide for intravenous (IV) administration has been done, and TXP-11 is readily manufactured and formulated by processes that can be scaled. Already the stability of the compound for several years, both on its own and in formulation, has been demonstrated.